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A B S T R A C T
The objective of the study was to assess the effect of age on the seroprevalence of Helicobacter (H.) pylori infection in
dyspeptic patients. The results obtained in the patient group were compared with findings on the seroprevalence of H.
pylori infection in 2051 blood donors. Serum samples were tested by the commercial ELISA and CFT assays according to
manufacturer’s instructions. The mean seroprevalence of H. pylori infection as determined by ELISA/CFT was 64.0%/
51.7% in the group of blood donors and 92.3%/89.5% in the group of dyspeptic patients. Study results indicated a higher
prevalence of H. pylori infection in dyspeptic patients as compared with blood donors in all age groups. In the patient
Sgroup, H. pylori seroprevalence was not age dependent.
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Introduction
Epidemiological studies conducted all over the world
have defined Helicobacter (H.) pylori infection as one of
the currently most common infections in humans1–5.
However, many issues related to the onset, dissemination
and rate of infection in different populations yet remain
to be elucidated4–7. Effects of particular factors of the mi-
croorganism virulence and characteristics of different
human populations in terms of clinical picture, infection
pattern and its possible late sequels have been continu-
ously investigated.
Man is the only recipient host for H. pylori. However,
gastric colonization with a H. pylori-like bacterium has
also been detected in cat and swine8–10. Epidemiological
studies conducted to date point to two routes of H. pylori
infection dissemination, fecal-oral and oral-oral. H. py-
lori was isolated from stool samples of children (Gambia)
and adults (Great Britain)11,12. The bacterium was also
isolated in dental plaque13. The rate of oral cavity coloni-
zation with H. pylori is very low in industrialized west-
ern countries, diminishing the role of oral-oral transmis-
sion (kissing, food)14,15.
Besides age, the prevalence of H. pylori infection is
mostly influenced by the socioeconomic status (over-pop-
ulation and poverty, especially in childhood; water con-
tamination; multi-member and poor families living in
cramped conditions) and place of residence16. In Great
Britain, the prevalence of H. pylori infection was consid-
erably greater in adults having lived in multi-member
families in their childhood. The prevalence was even
greater in the individuals that used to share bed with one
or more family members or having lived in a household
without running water during childhood17. The reason
for these findings most probably lies in long-term close
interpersonal contacts along with low hygiene condi-
tions18. In some countries (Peru), contaminated water
supply may be the source of H. pylori infection19.
Pets (e.g., cat) probably are another possible source of
infection20. H. pylori infection may also be transmitted
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on endoscopic examination; transmission of the infection
was recorded in 1–3% of endoscopic examinations with
manual endoscope washing, but not in endoscopy units
using mechanical endoscope cleaning and sterilization21.
Some professions22,23, among them health professionals,
GI endoscopy laboratory staff in particular, are at an in-
creased risk of H. pylori infection24,25.
In western countries, the prevalence of H. pylori in-
fection can generally be characterized as follows: (a) H.
pylori is present in approximately 20% of individuals be-
low 40 and in 50% of individuals over 60 years of age; (b)
H. pylori infection is a rare or unusual disease in small
children; (c) the lower the socioeconomic status, the
higher the prevalence of H. pylori infection; and (d) the
high prevalence ofH. pylori infection in some areas of in-
dustrialized countries is consequential to the increased
immigration of infected persons4,5,26. Current studies in-
dicate low incidence ofH. pylori infection in children and
young individuals. The high incidence of the infection in
adults is consequential to long-standing and permanent
infection acquired in childhood, along with the impact of
low socioeconomic conditions27.
In contrast to industrialized countries, in the major-
ity of developing countries (Brazil, Asia, Africa, and East
Europe) H. pylori infection is found in almost all adult
individuals. In these regions, the infection is already
present in 10% of children aged 2–8; in adolescence, the
incidence rises to 85–95%1,2,28,29.
Seroprevalence of H. pylori infection was also as-
sessed in dyspeptic patients. Some authors report a com-
parable seroprevalence of H. pylori infection in symp-
tomatic and asymptomatic subjects2,5–7,30–32, whereas
others found it to be higher in dyspeptic subjects as com-
pared with blood donors33–35.
Considering the increasing seroprevalence of H. py-
lori infection with age and variable results reported in
dyspeptic patients, we embarked upon the present study
to assess the effect of age on the seroprevalence of H.
pylori infection in patients with dyspeptic complaints.
The results recorded in the group of dyspeptic patients
were compared with those obtained in blood donors serv-
ing as a control group of normal population.
Materials and Methods
Serum samples
The presence of specific H. pylori antibodies was de-
termined in 2701 serum samples, including 650 patients
with clinical indications for gastric and duodenal endos-
copy (pain in upper abdomen with dyspeptic symptoms)
and 2051 healthy subjects (blood donors). Patients were
recruited from two hospitals: Sveti Duh General Hospi-
tal from Zagreb and Karlovac General Hospital from
Karlovac. Out of 650 patients, 500 (300 male and 200 fe-
male, mean age 55.3 years) regularly attended Endos-
copy Laboratory, Sveti Duh General Hospital, whereas
the remaining 150 patients (135 male and 15 female,
mean age 42.5 years) attended Endoscopy Laboratory,
Karlovac General Hospital (Table 1).
Serum samples were stored at –20 °C until analysis.
The study was conducted at the two hospitals during the
2001–2006 period.
Questionnaire
All study subjects filled out a questionnaire contain-
ing data on age and upper abdominal discomforts. Data
on dyspeptic complaints and/or treatment for gastric or
duodenal peptic disease were only entered by the patient
group.
Detection of H. pylori antibodies
Serum samples were tested with commercial enzyme-
-linked immunosorbent assay (ELISA; Eurospital, Trie-
ste, Italy) and complement fixation test (CFT; Institute
Virion, Zurich, Switzerland). The tests were performed
according to the manufacturer’s instructions. Borderline
test values were established in line with the manufac-
turer’s instructions to interpret the results obtained.
ELISA: each serum sample diluted 1:200 was applied
onto a microtiter plate with previously bound H. pylori
antigen. The antigen-antibody complex was proven by
sheep antihuman IgG antibodies labeled with alkaline
phosphatase and incubated with chromogen substrate.
The substrate absorption was determined by ELISA rea-
der (Multiscan, Titertek, MCC/340, Finland). An index of
IgG antibodies equal or higher than 40% was considered
as positive result.
CFT: complement fixation antibodies (IgM, IgG) were
proven by H. pylori strain Lior type 1. Each serum sam-
ple was diluted with a 1:10 Veronal buffer and incubated
for 30 minutes at 56 °C to inactivate the complement
present in the serum. Then serum samples as well as pos-
itive and negative serum controls were diluted from 1:10
to 1:160, with the addition of the respective antigen and
complement dilution. The test included controls to detect
anticomplement activity in each sample tested as well as
the control for the complement used (0.5, 1.0, 1.5 and 2.0
units of complement). CFT result was assessed on the ba-
sis of hemolysis inhibition. The inhibition of 50% or more
was considered positive, indicating the presence of anti-
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TABLE 1
BASELINE PATIENT CHARACTERISTICS
Patient group (institution) N
Mean
age (yrs)
Sveti Duh General Hospital
Male
Female
500
300
200
55.3
54.9
55.5
Karlovac General Hospital
Male
Female
150
135
15
42.5
42.8
41.5
Total 650 52.9
bodies in the respective dilution. Antibody titer of less
than 1:30 was considered negative.
Statistics
The c2-test for dependent and independent samples,
and the test of proportions were used. Statistical analysis
was done by use of the Microstat software. Statistical sig-
nificance was set at p<0.05.
Results
In the study group of 650 dyspeptic patients divided
according to age groups, neither c2-test nor the test of
proportions yielded any statistically significant differ-
ence between the seroprevalence of H. pylori infection as
determined by the ELISA and CFT (Table 2).
ELISA and CFT were used to test 2051 serum sam-
ples obtained from blood donors living in the Zagreb
area. The c2-test showed no statistically significant dif-
ference between the seroprevalence ofH. pylori infection
as determined by ELISA and CFT in serum samples of
blood donors divided according to age groups (Table 3).
However, the test of proportions indicated a statistically
significantly higher seroprevalence of H. pylori infection
by ELISA as compared with CFT in all age groups (29):
Z=9.13, p<0.001; (30–39): Z=3.58, p<0.001; (40–49):
Z=3.90, p<0.001; and (50): Z=6.98, p<0.001).
The proportions tested according to age groups re-
vealed an increase in the proportion of positive results
with age both by ELISA (29/30–39): Z=2.17, p<0.01;
(30–39/40–49): Z=1.58, p<0.05; and (40–49/50): Z=3.78,
p<0.001) and by CFT (29/30–39): Z=6.79, p<0.001;
(30–39/40–49): Z=2.54, p<0.05; (40–49/(50): Z=5.49,
p<0.001). The recorded seroprevalence proportions ac-
cording to age groups pointed to a gradual rise in the pro-
portion of positive infection with age only in the control
group of blood donors. In the study group of dyspeptic
patients, however, inspite of the higher prevalence of H.
pylori infection, age had no major impact on the sero-
prevalence proportion. Both ELISA and CFT methods
yielded a statistically significantly higher number of pos-
itive results in all patient age groups as compared with
the respective age groups of blood donors: ELISA (29):
Z=3.29, (30–39): Z=4.78, (40–49): Z=6.72, and (50):
Z=6.12 (p<0.001 all) and CFT (29): Z=4.63, (30–39):
Z=6.88, (40–49): Z=8.09, (50): Z=4.93 (p<0.001 all)
(Table 2 and 3).
Discussion
Endoscopic approach is a basis of all invasive diagnos-
tic methods with targeted biopsy sampling for detection
of H. pylori infection36. Such an approach is not accept-
able for epidemiological studies because it is very expen-
sive and uncomfortable for the patient. Of the noninva-
sive methods available, serology is the method of choice
for epidemiological studies. In addition, antibody detec-
tion in serum samples obtained at different times in the
course of infection and stored frozen until analysis allows
for the characteristics of the course of chronic infection
to identify.
Serologic methods are characterized by high specific-
ity, verifying the presence of H. pylori infection in sero-
positive individuals with high certainty, while the high
sensitivity of these methods ensures identification of
nearly all infected individuals. The serologic methods
employed in the present study were previously demon-
strated to have sensitivity over 90% and specificity of
about 80%37.
Serologic methods are preferred for detection of H.
pylori infection in patients with atrophic gastritis38–40
and bleeding ulcers41–43. The Western blot technique has
been increasingly employed to detect H. pylori antigen
antibodies (VacA, CagA), which point to an increased risk
of ulcer disease and gastric adenocarcinoma44–46.
Although the seroprevalence rate determined in vol-
unteers or blood donors cannot be considered represen-
tative for the respective population at large, such studies
point to the proportional seropositivity increase with
age47. In their study, Babu{ et al. found the mean sero-
prevalence of H. pylori infection in Croatia to be 60.4%
(95% CI 58.7–62.1%)48. The rate of infection increases
with the population aging, ranging from 51.6% in the
M. Maru{i} et al.: Helicobacter Pylori Seroprevalence in Dyspepsia, Coll. Antropol. 32 (2008) 4: 1149–1153
1151
TABLE 2
SEROPREVALENCE OF H. PYLORI INFECTION IN DYSPEPTIC
PATIENTS ACCORDING TO AGE GROUPS
Age group (yrs) N
ELISA (+)
n (%)
CFT (+)
n (%)
29* 64 52 (81.2) 47 (73.4)
30–39* 101 93 (92.7) 87 (86.1)
40–49* 158 150 (94.9) 147 (93.0)
50* 327 305 (93.9) 301 (92.0)
Total 650 600 (92.3) 582 (89.5)
N – total number of patients tested, (+) – Helicobacter pylori
positive patients, ELISA – enzyme-linked immunosorbent assay,
CFT – complement fixation test, *p<0.001 (Table2/Table3)
TABLE 3
SEROPREVALENCE OF H. PYLORI INFECTION IN BLOOD
DONORS ACCORDING TO AGE GROUPS
Age group
(yrs)
N
ELISA (+)
n (%)
CFT (+)
n (%)
29* 218 114 (52.2)** 77 (35.3)**
30–39* 743 454 (61.1)** 351 (47.2)**
40–49* 787 510 (64.8)** 421 (53.4)**
50* 303 235 (77.5)** 211 (69.6)**
Total 2051 1313 (64.0) 1060 (51.7)
N – total number of patients tested, (+) – Helicobacter pylori
positive subjects; ELISA – enzyme-linked immunosorbent assay,
CFT – complement fixation test, *p<0.001 (Table2/Table3),
**p<0.001
third decade of life through nearly 70% in the sixth de-
cade of life. In our study, the seroprevalence of H. pylori
infection in blood donors from the City of Zagreb as de-
termined by ELISA (64.0%) exceeded the figure yielded
by CFT (51.7%) as well as the mean rate for Croatia
(60.4%). The prevalence of H. pylori infection was defi-
nitely greater in dyspeptic patients (Table 2) than in
blood donors (Table 3): 92.3% vs. 64.0% by ELISA and
89.5% vs. 51.7% with CFT. In the group of dyspeptic pa-
tients, there was no statistically significant difference in
the proportion of H. pylori infection positivity according
to age groups. Our results confirmed literature reports
on the seroprevalence increase with the population
aging30,48,49 and on the higherH. pylori seroprevalence in
patients with dyspeptic complaints33–35. In countries with
a high rate of H. pylori seroprevalence, i.e. developing
countries, there will probably be no statistically signifi-
cant difference in H. pylori seroprevalence between
asymptomatic individuals and dyspeptic patients6. Schil-
ling et al. found no difference in H. pylori seroprevalence
according to dyspeptic patient subgroups35.
The present study demonstrated the value, reliability
and justifiability of the use of complement binding reac-
tion (CFT) and immunoenzyme testing (ELISA) in sero-
epidemiological studies. Results of our study support the
use of serology as the method of choice in epidemiological
studies. Although the seroprevalence determined in blood
donors cannot be considered representative for the re-
spective population, the results obtained indicated a pro-
portional age related increase in the rate of seropositivity
in the Zagreb population. The prevalence of H. pylori in-
fection was found to be greater in dyspeptic patients in
all age groups as compared with blood donors. In the for-
mer, however, the rate of H. pylori seroprevalence was
not age dependent.
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SEROPREVALENCIJA INFEKCIJE H. PYLORI U BOLESNIKA S DISPEPTI^NIM TEGOBAMA
S A @ E T A K
Ovim radom `eljeli smo utvrditi utjecaj `ivotne dobi na seroprevalenciju infekcijeHelicobacter pylori kod bolesnika s
dispepti~nim tegobama. Dobivene nalaze usporedili smo s nalazima seroprevalencije ove infekcije u 2051 dobrovoljnog
darovatelja krvi. Uzorci seruma testirani su komercijalnim pripravcima ELISA i CFT prema uputama proizvo|a~a. U
skupini dobrovoljnih darovatelja krvi prosje~na seroprevalencija infekcije bila je 64,0%/51,7% (ELISA/CFT), a u skupini
bolesnika s dispepti~nim tegobama 92,3%/89,5% (ELISA/CFT). Rezultati rada ukazuju na ve}u u~estalost infekcije H.
pylori u bolesnika nego kod dobrovoljnih darovatelja krvi po svim dobnim skupinama, a u skupini bolesnika je utvr|eno
da seroprevalencija H. pylori ne ovisi o `ivotnoj dobi.
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